Imiquimod cream efficacy in the treatment of periocular nodular basal cell carcinoma: a non-randomized trial

The recurrence rate of periocular nodular basal cell carcinoma (PNBCC) following treatment with imiquimod (IMQ) has not yet been established. Previous studies did not include histological follow-up. The aim of this analysis was to evaluate the efficacy of topical immunotherapy with 5% IMQ cream for...

Full description

Saved in:
Bibliographic Details
Published in:BMC ophthalmology 2015-04, Vol.15 (1), p.35-35, Article 35
Main Authors: de Macedo, Erick Marcet Santiago, Carneiro, Rachel Camargo, de Lima, Patricia Picciarelli, Silva, Breno Gonçalves, Matayoshi, Suzana
Format: Article
Language:English
Subjects:
Administration, Topical
Aged
Aminoquinolines - administration & dosage
Analysis
Antineoplastic Agents - administration & dosage
Carcinoma, Basal Cell - diagnosis
Carcinoma, Basal Cell - drug therapy
Eyelid Neoplasms - diagnosis
Eyelid Neoplasms - drug therapy
Female
Follow-Up Studies
Health aspects
Humans
Male
Medical research
Medicine, Experimental
Neoplasm Recurrence, Local
Prospective Studies
Skin Cream - administration & dosage
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The recurrence rate of periocular nodular basal cell carcinoma (PNBCC) following treatment with imiquimod (IMQ) has not yet been established. Previous studies did not include histological follow-up. The aim of this analysis was to evaluate the efficacy of topical immunotherapy with 5% IMQ cream for the treatment of PNBCC. A prospective, non-randomized, and uncontrolled longitudinal case series study. No participants were blinded. Punch biopsy confirmed PNBCC patients were included at the Ophthalmology Clinic of São Paulo University Medicine School Hospital (from 2008 to 2012). Patients were treated with 5% IMQ cream once a day, 5 days per week, for 8-16 weeks. Standard lesion photographic documentation was done during the study. Three months after treatment ended, an image-guided biopsy was performed. Patients were followed at 6-month intervals and annually for control biopsies. Main outcome measures were clinical and histological clearance rates. Data were analysed by frequency distribution for qualitative group characteristics and central tendency measures for quantitative data. Twenty-four patients met the inclusion criteria, 19 of whom remained until the end of treatment. The histological clearance rate was 89.5% and 84.2%, respectively, at 3 and 39.5 months. The 3-year histological clearance rate was 81.8% (9/11) for lesions >10 mm, and 100% (8/8) for lesions
ISSN:1471-2415
1471-2415
DOI:10.1186/s12886-015-0024-0